Sagar Raj Shakya

US Patent:

8183385, May 22, 2012

Filed:

Jun 21, 2006

Appl. No.:

11/917998

Inventors:

John DeMattei - San Diego CA, US
Sagar Shakya - Longmont CO, US
Paul J. Nichols - Boulder CO, US
Bradley R. Barnett - Boulder CO, US
Bruno P. Hache - Boulder CO, US
Matthew Charles Evans - Macclesfield, GB
James Gair Ford - Macclesfield, GB
John Leonard - Macclesfield, GB

Assignee:

Array BioPharma Inc. - Boulder CO
AstraZeneca AB - Sodertalje

International Classification:

C07C 235/08

US Classification:

5483044

Abstract:

Provided are methods for the synthesis of heterocyclic compounds such as benzimidazole carboxylic acid core structures having Formula Ia-2 and their synthetic intermediates: wherein X, X, X, R, Rand Rare as defined herein. Compounds of Formula Ia-2 and their synthetic intermediates can be used to prepare heterocyclic derivatives such as benzimidazole derivatives.

US Patent:

8383832, Feb 26, 2013

Filed:

Sep 9, 2011

Appl. No.:

13/229459

Inventors:

John Demattei - Berthoud CO, US
Sagar Shakya - San Diego CA, US
Anthony D. Piscopio - Longmont CO, US
Bruno P. Hache - Boulder CO, US
Matthew Charles Evans - MacclesField, GB
James Gair Ford - Macclesfield, GB
Simon Mark Pointon - Macclesfield, GB
Koen Peeters - Wetteren, BE
Timothy John Lilley - Macclesfield, GB
John Leonard - Macclesfield, GB

Assignee:

Array BioPharma Inc. - Boulder CO
AstraZeneca AB - Sodertalje

International Classification:

C07D 235/04
C07D 403/02
C07D 235/18

US Classification:

5483047, 5483061, 5483107

Abstract:

Provided are methods for the synthesis of heterocyclic compounds such as benzimidazole carboxylic acid core structures having Formula Ib-1:.

US Patent:

8501956, Aug 6, 2013

Filed:

Sep 9, 2011

Appl. No.:

13/229491

Inventors:

John Demattei - Berthoud CO, US
Sagar Shakya - San Diego CA, US
Anthony D. Piscopio - Longmont CO, US
Bruno P. Hache - Boulder CO, US
Matthew Charles Evans - MacclesField, GB
James Gair Ford - Macclesfield, GB
Simon Mark Pointon - Macclesfield, GB
Koen Peeters - Wetteren, BE
Timothy John Lilley - Macclesfield, GB
John Leonard - Macclesfield, GB

Assignee:

Array BioPharma Inc. - Boulder CO
AstraZeneca SB

International Classification:

C07D 235/06
C07D 235/08
C07D 403/04
C07D 403/06

US Classification:

5483044, 5483047, 5483061, 5483107

Abstract:

Provided are compounds having Formula VIIIa-1:.

US Patent:

20100145065, Jun 10, 2010

Filed:

Jun 21, 2006

Appl. No.:

11/993745

Inventors:

John Demattei - Berthoud CO, US
Sagar Shakya - Longmont CO, US
Anthony D. Piscopio - Boulder CO, US
Bruno P. Hache - Boulder CO, US
Matthew Charles Evans - Cheshire, GB
James Gair Ford - Cheshire, GB
Simon Mark Pointon - Cheshire, GB
Koen Peeters - Mont-Saint-Guibert, BE
Timothy John Lilley - Cheshire, GB
John Leonard - Manchester, GB

Assignee:

ARRAY BIOPHARMA INC. - Boulder CO

International Classification:

C07D 235/04
C07C 229/60
C07C 205/58

US Classification:

5483044, 560 47, 562437

Abstract:

Provided are methods for the synthesis of heterocyclic compounds such as benzimidazole carboxylic acid core structures having Formula Ia-1 and their synthetic intermediates: wherein Z, X, X, X, Rand Rare as defined herein. Compounds of Formula Ia-1 and their synthetic intermediates can be used to prepare heterocyclic derivatives such as benzimidazole derivatives.

US Patent:

20120225937, Sep 6, 2012

Filed:

Sep 21, 2010

Appl. No.:

13/497616

Inventors:

Anthony C. Blackburn - San Diego CA, US
Sagar Raj Shakya - San Diego CA, US
John A. DeMattei - Berthoud CO, US
Tsung-Hsun Chuang - San Diego CA, US

Assignee:

Arena Pharmaceuticals, Inc. - San Diego CA

International Classification:

A61K 31/27
A61P 9/12
A61P 7/02
A61P 9/10
A61P 9/00
A61P 27/06
A61P 25/02
A61P 13/12
A61P 27/02
A61P 29/00
A61P 17/06
A61P 19/02
A61P 37/06
A61P 25/00
A61P 37/00
A61P 1/04
A61P 17/10
A61P 3/10
A61P 11/00
A61P 11/06
A61P 1/00
C07C 309/15

US Classification:

514488, 560 27

Abstract:

The present invention relates to salts of 2-(2-((4-(((4-chlorophenyl)(phenyl)-carbamoyloxy)methyl)cyclohexyl)methoxy)acetamido)ethanesulfonic acid (Compound 1) and crystalline forms, solvates and hydrates thereof. The present invention further relates to processes and intermediates useful in the preparation of Compound I and salts, solvates and hydrates thereof. Crystalline forms, salts, solvates and hydrates of the present invention and pharmaceutical compositions thereof are useful in the treatment of for example, pulmonary arterial hypertension (PAH); platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; atherosclerosis; acne; type I diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).

US Patent:

20230052703, Feb 16, 2023

Filed:

Dec 12, 2019

Appl. No.:

17/616124

Inventors:

- Alameda CA, US
Khalid Shah - Half Moon Bay CA, US
Sagar Shakya - San Diego CA, US
Peter Wong - Brisbane CA, US
Courtney S. Johnson - West Lafayette IN, US
Melanie Janelle Bevill - West Lafayette IN, US
Stephan D. Parent - West Lafayette IN, US

International Classification:

C07D 215/48

Abstract:

The present invention relates to crystalline forms of salts of Compound 1. The invention also relates to pharmaceutical compositions comprising the solid crystalline salts of Compound 1. The invention further relates to methods of treating a disease, disorder, or syndrome mediated at least in part by modulating in vivo activity of a protein kinase.

US Patent:

20230029213, Jan 26, 2023

Filed:

Dec 12, 2019

Appl. No.:

17/312658

Inventors:

- Alameda CA, US
Khalid Shah - Half Moon Bay CA, US
Sagar Shakya - San Diego CA, US
Peter Wong - Brisbane CA, US
Courtney S. Johnson - West Lafayette IN, US
Melanie Janelle Bevill - West Lafayette IN, US
Stephan D. Parent - West Lafayette IN, US

International Classification:

C07D 215/48

Abstract:

The present invention relates to crystalline forms of the free base of the c-Met inhibitor, Compound 1. The invention also relates to crystalline forms of salts of Compound 1. The invention also relates to pharmaceutical compositions comprising the solid polymorphs of the free base and salts of Compound 1. The invention further relates to methods of treating a disease, disorder, or syndrome mediated at least in part by modulating in vivo activity of a protein kinase.

US Patent:

20200361869, Nov 19, 2020

Filed:

Apr 30, 2020

Appl. No.:

16/862681

Inventors:

- San Diego CA, US
Ryan O. Castro - San Diego CA, US
Mark Allen Hadd - San Diego CA, US
You-An Ma - Poway CA, US
Antonio Garrido Montalban - San Diego CA, US
Jaimie Karyn Rueter - San Diego CA, US
Lee Alani Selvey - Longview WA, US
Sagar Raj Shakya - San Diego CA, US
Marlon Carlos - Chula Vista CA, US

International Classification:

C07D 209/94
C07C 279/12

Abstract:

The present invention relates to, inter alia, a novel crystalline free-plate habit or morphology, processes for preparing the crystalline free-plate habit, and uses of the crystalline free-plate habit of the L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid (Compound 1) in the treatment of S1Preceptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditions characterized by an underlying defect in the vascular integrity or that are associated with angiogenesis such as may be pathologic (e.g., as may occur in inflammation, tumor development, and atherosclerosis).